

# WHO Drug Information

---

## Contents

### General Policy Topics

ICDRA: an influential forum for drug regulators 43

### Reports on Individual Drugs

Antiplatelet therapy: enthusiasm tempered by caution 45

BCG vaccine: a reappraisal of efficacy 46

Caffeine: a risk factor in pregnancy? 48

Safer treatments for haemophilia in prospect 50

Hepatitis B vaccines: immunogenicity reappraised 52

Iron supplementation and pregnancy 54

Zidovudine: lack of effect in asymptomatic patients 57

### General Information

Adjuvant therapy in cancer 58

Visceral leishmaniasis: deficiencies in management 60

More on multidrug-resistant tuberculosis 60

Ambivalence in tobacco control 63

### Regulatory Matters

Alpidem: hepatotoxicity results in withdrawal 65

Screening of blood and plasma products for transmissible pathogens 65

Botulinum toxin and severe dysphagia 65

Clozapine and myocarditis 66

Cyproheptadine: no longer promoted as an appetite stimulant 66

Postmenopausal estrogen therapy: requirement for concomitant progestogen administration 66

Ethylene oxide: limitations on its use in the manufacture of pharmaceuticals 67

Homoeopathic products: requirements for registration 67

Moxisylyte: dose-related hepatitis 67

Nicotine patches: cardiovascular reactions 68

High-lipase pancreatins: reports of colonic strictures 68

Pneumococcal vaccination: policy guidelines 68

Remoxipride: aplastic anaemia 69

Tamoxifen: stronger warning on uterine cancer 69

Thymoxamine and hepatotoxicity 70

### Consultative Document

Interchangeable multi-source pharmaceutical products: WHO draft guideline on marketing authorization requirements 71

### Proposed International

Nonproprietary Names: List 71 85